MedTrace Logo

Neutrophil Gelatinase-associated Lipcalin(NGAL): A Novel Blood Marker for Determining the Risk of Developing Contrast-Induced Nephopathy

NCT00693329 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 260

Last updated 2009-12-18

No results posted yet for this study

Summary

This is a multi-center clinical study designed to assess the performance of the Triage NGAL test as an aid in the early risk assessment for contrast-induced nephropathy (CIN). Approximately 260 adults at risk for CIN undergoing intra-arterial angiography involving administration of iodinated contrast agent(s) will be enrolled.

Conditions

  • Cardiovascular Surgery With Coronary Angiography

Sponsors & Collaborators

  • Abbott RDx Cardiometabolic

    lead OTHER

Principal Investigators

  • Peter McCullough, MD · William Beaumont Hospitals

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2009-06-30
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00693329 on ClinicalTrials.gov